Accueil   Diary - News   All news Nosopharm bolsters supervisory board

Nosopharm bolsters supervisory board

Gilles Alberici and Marie-Paule Richard join Nosopharm’s supervisory board, which is now fully operational.  These new appointments consolidate the company 's position as aninnovative player in the field of antibacterial and antifungal treatmentse




Lyon, France, December 6, 2017 - Nosopharm, a company dedicated to the research and development of new anti-infective drugs, today announces the appointment of Marie-Paule Richard and Gilles Alberici to its supervisory board. Alberici will be its new chairman. These new appointees will strengthen Nosopharm’s board with their expert knowledge of the pharmaceutical industry and skills in the development of new antiinfective therapies. They join Nosopharm’s existing supervisory board members: Gwenaël Hamon (Kreaxi, investment manager), Franck Lescure (Auriga Partners, partner) and Bernard Rivière (historic shareholder).


Gilles Alberici, PharmD, PhD, has 30 years experience in the European pharmaceutical industry, having established several innovative biopharmaceutical companies. He joined the Mérieux Group in 1986 and founded IMTIX, a company specializing in immunosuppression, in 1994. In 2000, he founded OPi, a company dedicated to rare and serious diseases. Since 2007, he has been chairman of Octalfa, an independent, familyowned company specializing in the creation, management and funding of life sciences companies.



Read the full press release